08/20/2026
🎉 A HUGE MOMENT FOR THE GSD COMMUNITY! 🎉
Ultragenyx has received FDA approval for GENGLYCOS, a prescription gene therapy used along with nutritional management to help reduce the amount of cornstarch taken daily in adults and children 8 years and older with Glycogen Storage Disease Type Ia (GSDIa).
For the GSD community, this moment represents so much more than a drug approval. It represents years of research, clinical trials, advocacy, courage, perseverance, and hope. ❤️
A HUGE thank you to everyone who helped make this happen — the patients, families, caregivers, researchers, doctors, advocates, and everyone who has worked tirelessly to move GSD research forward.
This is an incredible milestone for our community, and there is so much more progress and hope for the future! 🎉
💙 Here’s to a new chapter for the GSD community!
To learn more about GENGLYCOS, visit www.GENGLYCOS.com